[Pharmacological management of inflammatory rheumatic conditions].

Abstract

Inflammatory rheumatic disorders are related to different pathophysiological mechanisms and, hence, their therapeutic management varies according to the underlying disease. Crystal-induced arthritis is characterized by its almost specific responsiveness to colchicine. Regarding ankylosing spondylitis, non steroidal anti-inflammatory drugs (NSAIDs) and TNF blockers are the cornerstones of pharmacological intervention whereas oral corticosteroids at conventional doses are of little value, if any. Conversely, corticosteroids are the drug of choice to treat polymyalgia rheumatica. Furthermore, low-dose corticosteroids were shown to be more effective than NSAIDs in patients with rheumatoid arthritis (RA). However, the main goal being to achieve remission, disease-modifying antirheumatic drugs, either synthetic, especially methotrexate, and/or biologic, such as TNF inhibitors, have a major role in the management of RA. Finally, enhanced understanding of molecular pathogenesis of inflammatory disorders may help to find out how to best target available drugs to right individuals in the future.

• Authors: Bernard Bannwarth
• Journal: Therapie (Therapie) 2011 Sep-Oct Vol. 66 Issue 5 Pg. 377-81 ISSN: 0040-5957 [Print] France
• Vernacular Title: Prise en charge thérapeutique de l'inflammation d'origine rhumatismale.
• PMID: 22031680 (Publication Type: English Abstract, Journal Article, Review)
• Copyright: © 2011 Société Française de Pharmacologie et de Thérapeutique.

Chemical References

• Antirheumatic Agents
• Gout Suppressants
• Colchicine

Topics

• Antirheumatic Agents (therapeutic use)
• Arthritis (drug therapy)
• Arthritis, Rheumatoid (drug therapy)
• Colchicine (therapeutic use)
• Gout (drug therapy)
• Gout Suppressants (therapeutic use)
• Humans
• Inflammation (drug therapy, pathology)
• Polymyalgia Rheumatica (drug therapy)
• Rheumatic Diseases (drug therapy, pathology, physiopathology)
• Spondylarthritis (drug therapy)